Myocardial Protection of Exenatide in AMI

NCT01580514 on ClinicalTrials.gov · last registry update 2012-04-19

Finished August 2011, after enrolling 127 people. Primary outcome, as filed: Infarct size. exenatide is approved in the US, but not for cardiovascular disease — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: COMPLETED
Phase: P4
Drug: exenatide
Bydureon, Byetta
Sponsor: Kyunghee University Medical Center
Sponsor type: Other
Enrollment: 127
Started: 2009-09
Primary completion: 2011-08 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Infarct size

Conditions studied

Myocardial Infarction

Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.